Curation
Fundraising
AMM
Estimated global market opportunity for menopause-related products and services by 2030.
Percentage of the NIH 2020 budget allocated to women's health research, including female-specific and predominant conditions.
Percentage of global healthcare R&D investments that target female-specific conditions beyond oncology.
Women drive 80% of healthcare decisions and fuel the $500B U.S. healthcare and beauty market, yet women’s R&D is a blind spot in the biotech field - it is underpriced and a massive opportunity.
While science drives breakthroughs like extended lifespans and everyday technologies, women’s health R&D is a black box. We know very little about female biology, yet we depend on it for the human population. ...
Accelerating innovation in fertility and reproductive technologies to address the global fertility crisis, with rates falling below replacement levels. As fertility becomes an existential challenge, we focus on advancing research, improving treatments, and pioneering technologies to empower individuals and secure humanity's future.
Understanding the biology of ovarian decline, identifying biomarkers of aging, and driving innovations to delay menopause onset. By focusing on ovarian aging, we aim to extend healthspan, improve quality of life, and address one of the most under-researched areas in healthcare.
Transforming gynecologic oncology by addressing the critical underfunding and understudy of gynecologic cancers, despite significant investments in women-specific cancers like breast cancer. We focus on advancing research, improving diagnostics, and developing innovative treatments to save lives and close this research gap.
The sustainability loop principle guides $ATH's design, where the value of AthenaDAO's intellectual property grows as research projects produce positive results. Successful commercialization of these projects fuels the growth of AthenaDAO's ecosystem...
AthenaDAO
Medium
Femtech World